{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:44:55Z","timestamp":1793868295957,"version":"4.6.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eururo.2026.04.005","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:50:04Z","timestamp":1778014204000},"page":"225-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer\u2013specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5570-8792","authenticated-orcid":false,"given":"David-Dan","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borna","family":"Tadayon Najafabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jethro C.C.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Earl","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre R.","family":"Zlotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda E.","family":"Hird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha K.","family":"Lofters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.D.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Rosella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Guyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.04.005_b0005","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.04.005_b0010","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1056\/NEJMe2509793","article-title":"Early detection of prostate cancer - time to fish or cut bait","volume":"393","author":"Vickers","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.005_b0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.urolonc.2024.06.022","article-title":"Controversies in prostate cancer screening","volume":"43","author":"Obiora","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.005_b0020","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial","volume":"360","author":"Andriole","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.005_b0025","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.005_b0030","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.005_b0035","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis","volume":"362","author":"Ilic","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.005_b0040","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/jnci\/djp278","article-title":"Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005","volume":"101","author":"Welch","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2026.04.005_b0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-077738","article-title":"Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study","volume":"386","author":"Vaccarella","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.005_b0050","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schr\u00f6der","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.04.005_b0055","article-title":"Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps","volume":"2","author":"Bratt","year":"2023","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.eururo.2026.04.005_b0060","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","article-title":"European study of prostate cancer screening - 23-year follow-up","volume":"393","author":"Roobol","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.005_b0065","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2024.4011","article-title":"Prostate-specific antigen screening and 15-year prostate cancer mortality: a secondary analysis of the CAP randomized clinical trial","volume":"331","author":"Martin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2026.04.005_b0070","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the european randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.005_b0075","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.2018.3712","article-title":"Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force","volume":"319","author":"Fenton","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2026.04.005_b0080","article-title":"Screening for prostate cancer","volume":"2013","author":"Ilic","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2026.04.005_b0085","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1503\/cmaj.140703","article-title":"Recommendations on screening for prostate cancer with the prostate-specific antigen test","volume":"186","author":"Bell","year":"2014","journal-title":"CMAJ"},{"key":"10.1016\/j.eururo.2026.04.005_b0090","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bju.14580","article-title":"Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial","volume":"123","author":"Pinsky","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.005_b0095","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2023.08.002","article-title":"Early detection of prostate cancer in the European Union: combining forces with PRAISE-U","volume":"84","author":"Van Poppel","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.005_b0100","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071082","article-title":"Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit","volume":"381","author":"Vickers","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.005_b0105","article-title":"Is it time for Canada to revisit its approach to prostate cancer screening?","volume":"49","author":"Nguyen","year":"2025","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.eururo.2026.04.005_b0110","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.euo.2021.06.006","article-title":"A European model for an organised risk-stratified early detection programme for prostate cancer","volume":"4","author":"Van Poppel","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.005_b0115","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2026.04.005_b0120","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/S0140-6736(24)00912-7","article-title":"Prostate Cancer UK launches the TRANSFORM trial","volume":"403","author":"Burki","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.04.005_b0125","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.005_b0130","unstructured":"Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.5 (updated August 2024). Cochrane; 2024. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook."},{"key":"10.1016\/j.eururo.2026.04.005_b0135","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eururo.2025.07.021","article-title":"Guidelines for meta-analyses and systematic reviews in urology","volume":"88","author":"Vickers","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.005_b0140","unstructured":"Covidence - Better Systematic Review Management. Accessed November 9, 2025. https:\/\/www.covidence.org\/."},{"key":"10.1016\/j.eururo.2026.04.005_b0145","doi-asserted-by":"crossref","unstructured":"Cao C, Arora R, Cento P, et al. Automation of systematic reviews with large language models. medRxiv. doi: 10.1101\/2025.06.13.25329541.","DOI":"10.1101\/2025.06.13.25329541"},{"key":"10.1016\/j.eururo.2026.04.005_b0150","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081199","article-title":"Development of ROBUST-RCT: risk of Bias instrument for Use in SysTematic reviews-for Randomised Controlled Trials","volume":"388","author":"Wang","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.005_b0155","unstructured":"Eldridge S, Campbell M, Campbell M, et al. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0): additional considerations for cluster-randomized trials. unisa.edu.au. Accessed November 14, 2025. http:\/\/www.unisa.edu.au\/contentassets\/72bf75606a2b4abcaf7f17404af374ad\/rob2-0_cluster_parallel_guidance.pdf."},{"key":"10.1016\/j.eururo.2026.04.005_b0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083864","article-title":"Core GRADE 4: rating certainty of evidence-risk of bias, publication bias, and reasons for rating up certainty","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.005_b0165","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJMc1515131","article-title":"Reevaluating PSA testing rates in the PLCO trial","volume":"374","author":"Shoag","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.005_b0170","article-title":"Core GRADE 5: rating certainty of evidence-assessing indirectness","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.005_b0175","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/pros.20017","article-title":"Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial","volume":"59","author":"Labrie","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2026.04.005_b0180","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.005_b0185","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081903","article-title":"Core GRADE 1: overview of the Core GRADE approach","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.005_b0190","article-title":"Core GRADE 2: choosing the target of certainty rating and assessing imprecision","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.005_b0195","article-title":"Core GRADE 3: rating certainty of evidence-assessing inconsistency","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.005_b0200","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1136\/bmjebm-2024-113077","article-title":"Rating certainty when the target threshold is the null and the point estimate is close to the null","volume":"30","author":"Zeng","year":"2025","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.eururo.2026.04.005_b0205","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083866","article-title":"Core GRADE 6: presenting the evidence in summary of findings tables","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.005_b0210","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.2018.0154","article-title":"Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial","volume":"319","author":"Martin","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2026.04.005_b0215","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.juro.2018.01.080","article-title":"Long-term outcome of a single intervention population based prostate cancer screening study","volume":"200","author":"Lundgren","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.005_b0220","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1113135","article-title":"Prostate-cancer mortality at 11 years of follow-up","volume":"366","author":"Schr\u00f6der","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.005_b0225","first-page":"827","article-title":"The impact of PLCO control arm contamination on perceived PSA screening efficacy","volume":"23","author":"Gulati","year":"2012","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.eururo.2026.04.005_b0230","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.purol.2020.02.011","article-title":"Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC)","volume":"30","author":"Villers","year":"2020","journal-title":"Prog Urol"},{"key":"10.1016\/j.eururo.2026.04.005_b0235","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/cncr.31178","article-title":"The efficacy of prostate-specific antigen screening: impact of key components in the ERSPC and PLCO trials","volume":"124","author":"de Koning","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2026.04.005_b0240","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.eururo.2019.04.007","article-title":"The impact of design and performance in prostate-specific antigen screening: differences between ERSPC centers","volume":"76","author":"Heijnsdijk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.005_b0245","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa1201637","article-title":"Quality-of-life effects of prostate-specific antigen screening","volume":"367","author":"Heijnsdijk","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.005_b0250","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35615","article-title":"Applicability of number needed to screen or invite as measures of cancer screening efficiency beyond clinical trials","volume":"7","author":"Doubeni","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2026.04.005_b0255","doi-asserted-by":"crossref","first-page":"E1441","DOI":"10.1503\/cmaj.180463","article-title":"Recommendations on screening for breast cancer in women aged 40-74 years who are not at increased risk for breast cancer","volume":"190","author":"Klarenbach","year":"2018","journal-title":"CMAJ"},{"key":"10.1016\/j.eururo.2026.04.005_b0260","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/0969141316648987","article-title":"Reduced breast cancer mortality after 20+ years of follow-up in the Swedish randomized controlled mammography trials in Malm\u00f6, Stockholm, and G\u00f6teborg","volume":"24","author":"Nystr\u00f6m","year":"2017","journal-title":"J Med Screen"},{"key":"10.1016\/j.eururo.2026.04.005_b0265","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1001\/jama.2024.5534","article-title":"Screening for breast cancer: US preventive services task force recommendation statement","volume":"331","author":"Force","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2026.04.005_b0270","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35669","article-title":"Delayed cancer registration and estimation of screening colonoscopy effects","volume":"7","author":"Brenner","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2026.04.005_b0275","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1503\/cmaj.151125","article-title":"Recommendations on screening for colorectal cancer in primary care","volume":"188","year":"2016","journal-title":"CMAJ"},{"key":"10.1016\/j.eururo.2026.04.005_b0280","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2208375","article-title":"Effect of colonoscopy screening on risks of colorectal cancer and related death","volume":"387","author":"Bretthauer","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.005_b0285","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1002\/cncr.30192","article-title":"Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: a microsimulation screening analysis","volume":"122","author":"Carlsson","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2026.04.005_b0290","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7326\/M16-2586","article-title":"Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials","volume":"167","author":"Tsodikov","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2026.04.005_b0295","article-title":"Prostate-specific antigen screening and prostate cancer mortality: an emulation of target trials in US medicare","volume":"8","author":"Garc\u00eda-Alb\u00e9niz","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.eururo.2026.04.005_b0300","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083800","article-title":"Prostate specific antigen retesting intervals and trends in England: population based cohort study","volume":"391","author":"Collins","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.005_b0305","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/jamaoncol.2025.3386","article-title":"Prostate-specific antigen levels among participants receiving annual testing","volume":"11","author":"Pickersgill","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.04.005_b0310","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200031","article-title":"Harm-to-benefit of three decades of prostate cancer screening in black men","volume":"1","author":"Basourakos","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.eururo.2026.04.005_b0315","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/jamainternmed.2023.3781","article-title":"Testing whether cancer screening saves lives: implications for randomized clinical trials of multicancer screening","volume":"183","author":"Welch","year":"2023","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.eururo.2026.04.005_b0320","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1200\/JCO.2011.40.4327","article-title":"Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force review","volume":"30","author":"Carlsson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.005_b0325","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/jamainternmed.2023.3798","article-title":"Estimated lifetime gained with cancer screening tests: a meta-analysis of randomized clinical trials","volume":"183","author":"Bretthauer","year":"2023","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.eururo.2026.04.005_b0330","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.26990","article-title":"Noncancer-related mortality in randomized clinical trials: a meta-analysis","volume":"8","author":"Lei","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2026.04.005_b0335","doi-asserted-by":"crossref","unstructured":"Nguyen DD, Kulkarni GS, Guyatt GH. Re: European study of prostate cancer screening - 23-year follow-up. Eur Urol. In press. https:\/\/doi.org\/10.1016\/J.EURURO.2025.12.009.","DOI":"10.1016\/j.eururo.2025.12.009"},{"key":"10.1016\/j.eururo.2026.04.005_b0340","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial","volume":"22","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.005_b0345","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/ijc.33940","article-title":"A randomized trial of risk-adapted screening for prostate cancer in young men-results of the first screening round of the PROBASE trial","volume":"150","author":"Arsov","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2026.04.005_b0350","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2024.04.030","article-title":"Risk-adjusted screening for prostate cancer-defining the low-risk group by data from the PROBASE trial","volume":"86","author":"Krilaviciute","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.005_b0355","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2016.66.7527","article-title":"Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer","volume":"34","author":"Preston","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.005_b0360","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12894-017-0281-8","article-title":"Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy","volume":"17","author":"Nordstr\u00f6m","year":"2017","journal-title":"BMC Urol"},{"key":"10.1016\/j.eururo.2026.04.005_b0365","doi-asserted-by":"crossref","unstructured":"Arvendell M, Abbadi A, Phillips L, Crippa A, Nordstr\u00f6m T, Lantz A. Socioeconomic status and prostate-specific antigen testing: a population-based cohort study comparing organised and opportunistic prostate cancer testing. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/J.EUF.2025.09.003.","DOI":"10.1016\/j.euf.2025.09.003"},{"key":"10.1016\/j.eururo.2026.04.005_b0370","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2025.3579","article-title":"Microultrasonography-Guided vs MRI-guided biopsy for prostate cancer diagnosis: the OPTIMUM randomized clinical trial","volume":"333","author":"Kinnaird","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2026.04.005_b0375","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.005_b0380","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.005_b0385","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2025.05.038","article-title":"Magnetic resonance imaging\u2013based biopsy strategies in prostate cancer screening: a systematic review","volume":"88","author":"Schoots","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.005_b0390","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(25)00100-7","article-title":"Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial","volume":"26","author":"Bryant","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.005_b0395","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1001\/jamaoncol.2024.4000","article-title":"Transperineal vs transrectal prostate biopsy-the PREVENT randomized clinical trial","volume":"10","author":"Hu","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.04.005_b0400","article-title":"Using real world data to bridge the evidence gap left by prostate cancer screening trials","volume":"6","author":"Norori","year":"2024","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"10.1016\/j.eururo.2026.04.005_b0405","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1002\/cncr.24446","article-title":"Anxiety and distress during active surveillance for early prostate cancer","volume":"115","author":"Van Den Bergh","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2026.04.005_b0410","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.eururo.2012.05.072","article-title":"Active surveillance for prostate cancer: a systematic review of the literature","volume":"62","author":"Dall\u2019Era","year":"2012","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382602107X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382602107X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:26:08Z","timestamp":1788740768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382602107X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S030228382602107X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.04.005","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer\u2013specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}